Belladonna


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Smooth muscle spasms 0.25-0.5 mg bid-tid Topical Muscular aches and pains As 0.25% w/w plaster: Apply 1 plaster to affected area as required.
Dosage Details
Oral
Smooth muscle spasms
Adult: 0.25-0.5 mg bid-tid.

Topical/Cutaneous
Muscular aches and pains
Adult: As 0.25% w/w plaster: Apply 1 plaster to affected area as required. Remove after 2-3 days.
Contraindications
Glaucoma, bronchial asthma, prostatic hyperplasia, urinary retention, tachycardia, circulatory insufficiency, ulcerative colitis, pyloric stenosis. Application to face (topical). Pregnancy and lactation.
Adverse Reactions
Significant: Hypersensitivity reactions (e.g. rash); local irritation (topical); dryness of oral mucosa, constipation, acceleration of heart function, accommodation disorder (long-term use).
Eye disorders: Pupil paralysis, increased intraocular pressure.
Gastrointestinal disorders: Constipation.
Psychiatric disorders: Depression, visual hallucinations.
Skin and subcutaneous tissue disorders: Dry skin, skin redness (topical).
Patient Counseling Information
This drug may cause accommodation disorders or visual hallucinations, if affected, do not drive or operate machinery. Avoid contact on broken, inflamed, sunburnt, cut or grazed skin (topical).
Overdosage
Symptoms: Reduced sweat and salivary secretions, double vision, photophobia, skin redness, rash, increased body temp, mydriasis, tachycardia, palpitation, excitement, disorientation, hallucinations, speech disorders, delirium, seizures, coma, headache, hyperthermia. Management: Administer activated charcoal to reduce absorption. May give physostigmine or neostigmine as primary antidote; IV barbituric acid for delirium states. Artificial respiration may be required if necessary.
Drug Interactions
Enhanced effect with amantadine, quinidine, TCAs, MAOIs, antihistamines and neuroleptics. May antagonise effect of metoclopramide, cholinesterase inhibitors and parasympathomimetics. May reduce action of phenothiazine. May increase absorption of atenolol, digoxin, thiazide diuretics. May reduce absorption of cimetidine and levodopa.
Action
Description: Belladonna contains several alkaloids derived from dried leaf and flowering tops of Atropa belladonna plant. It blocks muscarinic receptors in peripheral tissues such as gastrointestinal, urinary-tract and bronchial smooth muscles, and secretory glands, principally resulting from its atropine content. It also desensitises the nerve endings associated with the pain response when applied topically.
Synonym: atropa belladonna, deadly nightshade.
Pharmacokinetics:
Absorption: Well absorbed from the gastrointestinal tract.
Distribution: Crosses the placenta.
Metabolism: Hydrolysed in the liver to tropine and tropic acid.
Excretion: Via urine (approx 33% as unchanged drug); faeces, lesser extent. Elimination half-life: 2-3 hours.
Storage
Store below 25ºC. Protect from light and heat.
Any unused portion should be disposed of in accordance with local requirement.
MIMS Class
References
Anon. Belladonna. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 27/04/2018.

Belladonna Plaster (Cuxson Gerrard & Co. Ltd.). MHRA. https://products.mhra.gov.uk/. Accessed 27/04/2018.

Buckingham R (ed). Belladonna. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 27/04/2018.

Disclaimer: This information is independently developed by MIMS based on Belladonna from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in